QGEN — QIAGEN N.V.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1015820 ·
Netherlands
Last close
$41.78
Market Cap
$8.63B
52W High
$45.53
52W Low
$34.78
ADV30
3,019,409
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 535,040,000 | 340,386,000 | 140,850,000 | 103,401,000 | 5,889,202,000 | 768,500,000 | 2,531,462,000 |
| Mar 2026 | 492,320,000 | 309,603,000 | 116,626,000 | 68,043,000 | 5,782,065,000 | 646,289,000 | 2,450,359,000 |
| Dec 2025 | 540,420,000 | 325,269,000 | 121,880,000 | 107,829,000 | 6,281,232,000 | 839,005,000 | 2,503,078,000 |
| Sep 2025 | 532,583,000 | 331,259,000 | 137,293,000 | 130,043,000 | 6,553,497,000 | 1,355,594,000 | 2,904,082,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$615,215,000
Investing CF
$-213,886,000
Financing CF
$-395,931,000
CapEx
$-211,343,000
Dividends Paid
$1,000
Buybacks
$0
EPS Diluted TTM
$1.94
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$2,802,017,000
Inventory
$309,606,000
Receivables
$396,616,000
ST Investments
$0
EBIT TTM
$493,558,000
Pretax Income TTM
$456,545,000
Interest Exp TTM
$37,013,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,100,363,008
EBITDA
$734,185,024
Free Cash Flow
$372,855,136
Enterprise Value
$9,960,433,664
Total Cash
$793,500,032
Total Debt
$1,653,698,944
Shares Out
206,495,000
Trailing EPS
$1.97
Book Value
$16.26
ROE
11.9%
ROA
5.9%
Div Yield
0.79%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,089,999,000 | 520,310,000 | 424,880,000 | 6,281,232,000 | 2,503,078,000 | — | 654,326,000 |
| Dec 2024 | 1,978,214,000 | 199,899,000 | 83,591,000 | 5,689,622,000 | 2,122,283,000 | — | 673,551,000 |
| Dec 2023 | 1,965,311,000 | 445,247,000 | 341,303,000 | 6,115,190,000 | 2,307,426,000 | — | 459,455,000 |
| Dec 2022 | 2,141,518,000 | 576,228,000 | 423,211,000 | 6,287,735,000 | 2,821,124,000 | — | 715,264,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.61
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $45.00 · spot: $41.78 · call volume: 4,223 · put volume: 306
Expected Move to 2026-12-18:
±$6.75
(16.16%) —
implied range
$35.03 –
$48.53
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TWST | Twist Bioscience Corp | $8.83B | $140.80 | — |
| APGE | Apogee Therapeutics, Inc. | $8.38B | $134.79 | — |
| IMVT | Immunovant, Inc. | $8.95B | $43.32 | — |
| PCVX | Vaxcyte, Inc. | $9.21B | $61.87 | — |
| IBRX | ImmunityBio, Inc. | $8.03B | $7.58 | — |
News headlines (Yahoo Finance, 1h cache)
Qiagen names Jonathan Pratt as CEO amid takeover talks
2026-08-24 14:26 · Yahoo
QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
2026-08-24 13:47 · Yahoo
4% Undervalued? Qiagen (QGEN) As Q2 Beat And FDA Clearance Lift The Story
2026-08-14 09:17 · Yahoo
Qiagen (QGEN) Beat Its Own Guidance, So Why Did Margins Slip?
2026-08-13 19:18 · Yahoo
Strong Beats Mask Zillow’s (Z) Restructuring And Headwinds
2026-08-13 18:50 · Yahoo
Will FDA Clearance of QIAstat-Dx Bloodstream Panel Change Qiagen's (QGEN) Syndromic Testing Narrative?
2026-08-13 12:10 · Yahoo
Qiagen (QGEN) Q2 2026 Earnings Call Transcript
2026-08-13 06:13 · Yahoo
QIAGEN Receives U.S. FDA Clearance for First QIAstat-Dx Bloodstream Infection Panel
2026-08-10 20:05 · Yahoo
Understanding Qiagen (QGEN) Reliance on International Revenue
2026-08-10 13:15 · Yahoo
Qiagen Q2 Earnings Call Highlights
2026-08-09 02:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.